Upsher-Smith Receives Tentative NDA Approval for Vogelxo(TM) (testosterone) Gel CIII
MAPLE GROVE, Minn., Aug. 16, 2013 /PRNewswire/ — Upsher-Smith Laboratories, Inc., today announced that it has received tentative approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Vogelxo(TM) (testosterone) gel for topical use CIII.
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded and generic pharmaceuticals. Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases and also markets products relating to cardiology, dermatology, and women’s health. For more information, visit www.upsher-smith.com.
SOURCE Upsher-Smith Laboratories, Inc.